Spanish brand LETI Laboratories targets US market for professional skin care

Barcelona-based LEFTI has developed its business in the European market for professional skin care with a line of products designed for atopic skin, known as AT4, which it now wants to expand into the fast growing category in North America.

DermWORX will market the product line to US Healthcare professionals and their patients beginning in the Autumn of 2014, through its established distribution network throughout the nation.

An established player in South America and Europe​

LEFTI Laboratories is an established player in the Spanish and European and South American markets. Having been established 95 years ago it specializes in biopharmaceuticals, skin care, allergy & immunology treatments and products.

“DermWORX and LETI share a passion for creating high-quality skin therapeutics and products that improve people’s lives, particularity those with compromised skin,”​ said Jaime Grego, President of LETI.

“LETI has earned the loyalty of physicians and their patients with safe and effective solutions like AT4. We are thrilled to make these products available in the United States through our partnership with DermWORX.”​

Within the professional skin care market, demand for allergy skin care treatments is growing as one in five people worldwide is said to experience skin allergy symptoms at some point in their lives.

The AT4 taps into this trend because it targets children and adults with atopic skin conditions, which is a common condition that leads to dry, scaly itchy and irritated skin that is often prone to rashes.

Growth of US professional skin care category​

The market for professional skin care products in the US has grown significantly, off the back of a continued rise in cosmetics surgery, as well as the growing use of professional dermatology services.

This trend was marked by the recent entry into the category of major cosmetics player Elizabeth Arden, when it launched its RX skin care line in the US back in March of this year.

The company says that the Rx skin care line will be setting a precedence because it will be for sale exclusively in physician’s offices, a move that is consistent with its strategy of targeting the prestige retail, spa and professional skin care markets in its bid for omni-channel market growth.